Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain.

Naunyn-Schmiedeberg's Archives of Pharmacology
David MorantaJesús A García-Sevilla

Abstract

Brain monoamines are involved in many neurochemical and behavioral effects of cannabinoids, but little is known on the regulation of noradrenaline, dopamine, and serotonin (5-HT) synthesis in cannabinoid addiction. This study investigated in rat brain the chronic effects of the potent cannabinoid agonist WIN 55,212-2 and of rimonabant-precipitated withdrawal, as well as the sensitivity of synthesis-modulating inhibitory receptors, on the accumulation of L-3,4-dihydroxyphenylalanine (DOPA) and 5-HTP after decarboxylase inhibition. Acute WIN (8 mg/kg; 1 h) increased DOPA synthesis in cortex (52%), hippocampus (51%), and cerebellum (56%) and decreased DOPA accumulation in striatum (31%). Acute WIN also decreased the synthesis of 5-HTP in all brain regions (40-53%). Chronic WIN (2-8 mg/kg; 5 days) and/or antagonist-precipitated withdrawal induced tolerance to the acute effects of WIN on the accumulation of DOPA (cortex and striatum) and 5-HTP (all brain regions). The inhibitory effect of clonidine (alpha2-agonist; 1 mg/kg) on the accumulation of DOPA (15-41%) and 5-HTP (22-41%) was markedly decreased or abolished after chronic WIN and precipitated withdrawal, mainly in noradrenergic and serotonergic brain regions, which indicated d...Continue Reading

References

Jun 1, 1992·Naunyn-Schmiedeberg's Archives of Pharmacology·F Pi, J A García-Sevilla
Jul 1, 1989·Physiological Reviews·K StarkeH Kilbinger
Nov 1, 1994·Naunyn-Schmiedeberg's Archives of Pharmacology·A U TrendelenburgN Limberger
Jun 1, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J D JentschR H Roth
Jan 1, 1997·Pharmacology & Therapeutics·R G Pertwee
Dec 24, 1997·Naunyn-Schmiedeberg's Archives of Pharmacology·E SchlickerM Göthert
Jun 15, 1999·Progress in Neurobiology·A Ameri
Aug 27, 1999·Naunyn-Schmiedeberg's Archives of Pharmacology·A Sastre-CollJ A García-Sevilla
Jan 29, 2000·Naunyn-Schmiedeberg's Archives of Pharmacology·M NakaziE Schlicker
Aug 30, 2000·Nuclear Medicine and Biology·L Lanfumey, M Hamon
Jan 12, 2001·Journal of Neurophysiology·G Gerdeman, D M Lovinger
Apr 3, 2001·European Journal of Pharmacology·M D AcetoB B Martin
Aug 18, 2001·Pharmacology, Biochemistry, and Behavior·D T Malone, D A Taylor
Nov 8, 2001·Trends in Pharmacological Sciences·E Schlicker, M Kathmann
Jan 29, 2002·Pharmacology, Biochemistry, and Behavior·Jano J JanoyanNissar A Darmani
Mar 8, 2002·Naunyn-Schmiedeberg's Archives of Pharmacology·Antoni Sastre-CollJesús A García-Sevilla
Jun 25, 2002·European Journal of Pharmacology·Nobuaki EgashiraMichihiro Fujiwara
Jan 4, 2003·Science·Diego J WaltherMichael Bader
Feb 24, 2004·Critical Reviews in Neurobiology·Laura J Sim-Selley
Mar 11, 2004·Journal of Neurochemistry·Analía BortolozziAlbert Adell
Jul 13, 2004·Science·Xiaodong ZhangMarc G Caron
Jul 22, 2004·British Journal of Pharmacology·Anna CastañéOlga Valverde

❮ Previous
Next ❯

Citations

Mar 1, 2012·Psychopharmacology·David R SchulzeLance R McMahon
Jun 14, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nathalie GinovartPhilippe Millet
Apr 20, 2010·Naunyn-Schmiedeberg's Archives of Pharmacology·Zdenek Fisar
Dec 3, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Susana Esteban, Jesús A García-Sevilla
Feb 22, 2011·Neuroscience·R MaldonadoP Robledo
Sep 6, 2015·The International Journal of Neuropsychopharmacology·Marie FitzgibbonMichelle Roche
Jan 16, 2010·The European Journal of Neuroscience·Ana F CarvalhoElisabeth J Van Bockstaele
Apr 8, 2016·Nature Reviews. Neuroscience·H Valerie CurranLoren H Parsons
Mar 1, 2011·Neuropharmacology·Samir Haj-Dahmane, Roh-Yu Shen
Sep 18, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Alfredo Ramos-MiguelJesús A García-Sevilla
Aug 16, 2017·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·F SarubboD Moranta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.